Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Critical Care portfolio products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
|Market Price at 19-10-2017
|Price to Earnings Ratio
|Return on Equity (ROE)
Blog posts that reference Edwards Lifesciences Corp:
Monday, July 24, 2017
• Healthy earnings and encouraging housing data support the US stock market.
• European markets finish lower as surging currency weighs on sentiment.
• Financial markets in China and India move higher, while those in Australia and Japan struggle.
Tuesday, February 21, 2017
• Relatively hawkish tone from Federal Reserve Chair Janet Yellen underpins rally in financial stocks.
• European equities edge higher following strong performance in by US equities.
• Most of the Asian equities finished up on account of strong domestic economic data.
Wednesday, February 10, 2016
Ever wondered if your investment prowess is able to beat the market? Skaffold has added a cool new feature that enables you to compare your portfolio’s performance with the market at the click of a button. Find out how to do this in Skaffold.
Tuesday, April 15, 2014
Healthcare represents less than one per cent of the ASX, one of the world’s most dynamic growth sectors.
That’s why most Aussie healthcare stocks trade at what’s known as a ‘scarcity premium’.
Encompassing healthcare facilities, drug and biotechnology stocks, and medical equipment suppliers and manufacturers, the overall quality and performance of Australian healthcare stocks is impressive. Half of the top 10 achieved Skaffold’s preferred stock ratings of A1, A2, B1 and B2 based on their latest financial reports.
Despite a recent sell off, which has seen share prices of the top 10 fall, on average, 3% since late February, safety margins continue to be high, ranging between -15 and -75 per cent.
With the ‘scarcity premium’ enshrouding local healthcare stocks, we went in search of better healthcare value stocks offshore and found 6 standouts.
Thursday, February 06, 2014
Investing in top stocks – businesses with solid balance sheets, good cash flow, impressive profitability and the capacity to drive future growth – will build a portfolio with an impressive mix of businesses and, over the long run, deliver returns that should outperform the market.
Skaffold interprets a company’s key fundamentals and economic indicators into image-rich visuals, making it easy to spot the best stocks and avoid those with a track record of disappointing shareholders
Wednesday, September 04, 2013
Seek Limited (SEK) has ended the 2013 financial year with more than $184 million cash in bank, improving the quality of its balance sheet and lifting its Skaffold Quality Score from B to A. Unfortunately the increase in total shareholders equity, coupled with higher debt, did not result in a material uplift in NPAT and SEK’s return on equity fell from close to 40% in 2012 to 24%, as at 30 June 2013. SEK is now rated A2 by Skaffold.
Companies to report improving business performance over the last six months include vitamin developer Blackmores (BKL), wealth management business SFG Australia (SFW), software developers Objective Corporation (OCL) and Prophecy International Holdings (PRO).
Friday, August 30, 2013
After a couple of weeks of relatively few new opportunities appearing in Skaffold, the flood gates have finally opened!
Vita Life Sciences (VSC) is the latest company to rise to A1 (from C2 no less!). The number of companies rated A2 was boosted overnight, to 83. Twenty-First Century Fox (FOX), Medusa Mining (MML) and Reverse Corp (REF) were a handful of companies that rose from A3 to A2.
Friday, August 23, 2013
The latest round of companies to update in Skaffold include BHP Billiton (BHP), QBE Insurance (QBE), Coca-Cola Amatil (CCL), Sonic Healthcare (SHL), BlueScope Steel (BSL), Breville Group (BRG) and BigAir Group (BGL).
Did you know that you can receive an email each morning letting you know when companies update in Skaffold. Its what we use to uncover new top quality opportunities every day.
Wednesday, March 06, 2013
It’s the last week of reporting season, and the upsets keep emerging. Regional airline Regional Express (REX) has held Skaffold’s second highest A2 Score for 5 of the past 10 years. REX has fallen to A3. So has Seymour Whyte. Other companies to update in Skaffold include Silver Lake Resources (SLR), Saracen Mineral Holdings (SAR), AV Jennings (AVJ), Corporate Travel Management (CTD), Global Construction Services (GCS), Harvey Norman (HVN), Challenger (CGF) and Perpetual (PPT).